EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Pi

Ensembl ID : ENSVPAG00000002443
Gene Symbol: GABRP
1 Cross references
124 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 2

Ensembl ID : ENSVPAG00000010399
Gene Symbol: GABBR2
1 Cross references
240 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSVPAG00000005363
Gene Symbol: GLP2R
1 Cross references
205 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSVPAG00000011309
Gene Symbol: GRIA2
1 Cross references
321 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 3

Ensembl ID : ENSVPAG00000006246
Gene Symbol: GRIA3
1 Cross references
318 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 4

Ensembl ID : ENSVPAG00000007633
Gene Symbol: GRIA4
1 Cross references
323 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 3a

Ensembl ID : ENSVPAG00000002247
Gene Symbol: GRIN3A
1 Cross references
245 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 1

Ensembl ID : ENSVPAG00000012421
Gene Symbol: GRIK1
1 Cross references
302 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSVPAG00000002662
Gene Symbol: GRIK2
1 Cross references
331 Possible Orthologues:

Glutamate Metabotropic Receptor 5

Ensembl ID : ENSVPAG00000000432
Gene Symbol: GRM5
1 Cross references
272 Possible Orthologues:

Glutaminase

Ensembl ID : ENSVPAG00000011542
Gene Symbol: GLS
1 Cross references
302 Possible Orthologues:

Glycogen Synthase Kinase 3 Beta

Ensembl ID : ENSVPAG00000003769
Gene Symbol: GSK3B
3 Cross references
241 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).